Synonyms: IMCgp100 | Kimmtrak® | tebentafusp-tebn
tebentafusp is an approved drug (FDA & EMA (2022))
Compound class:
Antibody
Comment: Tebentafusp (IMCgp100) is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3-4]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to restore immune surveillance and T-cell-directed killing of specific cancer cells.
|
Bioactivity Comments |
Affinity of the antibody for the engagement of the TCR is reported to be in the picomolar range [2]. We cannot find information regarding the affinity for the CD3e interaction. |